http://www.etnet.com.hk/www/eng/futures/futures_news_detail.php?newsid=ETE330414895 Web4 apr. 2024 · Continuing to invest the massive profits generated from its COVID-19 vaccine Comirnaty success, German biotech BioNTech has signed up for another oncology collaboration. China’s Junshi Biosciences has entered an agreement with Rxilient Biotech (a portfolio company of Legend Capital), to form a ...
和黃醫藥投資(香港)有限公司 - 企查查
Web12 apr. 2024 · Hong Kong, Shanghai & Florham Park, NJ — Wednesday, April 12, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new and updated clinical and non-clinical data related to five HUTCHMED investigational drug candidates will be presented during the American Association for … Web2 dagen geleden · HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2024. HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM, HKEX: 13) today announces that new and … today\u0027s date in polish
HUTCHMED Launches Hong Kong Initial Public Offering - Yahoo …
Web30 sep. 2002 · 简介:和记黄埔医药 (上海)有限公司隶属于和黄中国医药科技有限公司 (Chi-Med),专注于研发针对癌症和自身免疫性疾病的靶向药物,致力于成为全球创新药研发领 … WebHUTCHMED Holdings (HK) Limited was incorporated on 21-JAN-2000 . HUTCHMED Investment (HK) Limited 和黃醫藥投資(香港)有限公司 Cr No. 1153075 Web18 jun. 2024 · Hutchmed (China) Limited (NASDAQ: HCM) will look to raise $603 million as part of a Hong Kong IPO, listed in the U.S., since 2016. The company plans to offer up to … today\u0027s date in russia